Khoury Mitri K, Mulaney-Topkar Bianca, Anjorin Aderike, Demsas Falen, Gaston Brandon J, Mohebali Jahan, Eagleton Matthew J, Srivastava Sunita D
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA; Division of Vascular and Endovascular Surgery, HonorHealth Heart Care, Scottsdale, AZ.
Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA.
J Vasc Surg. 2025 Aug;82(2):401-408.e1. doi: 10.1016/j.jvs.2025.04.026. Epub 2025 Apr 19.
Cervical debranching was traditionally performed for occlusive disease of the proximal cervical branches of the aortic arch. However, as endovascular technology has evolved, cervical debranching is more commonly performed to optimize proximal landing zones for thoracic endovascular aortic repair (TEVAR). Cervical debranching and TEVAR can be performed in either a staged or synchronous fashion with little-to-no data regarding the optimal treatment strategy. Therefore, the purpose of this study was to evaluate outcomes of patients undergoing cervical debranching and TEVAR in a staged vs synchronous fashion.
This was a retrospective single-center review of patients undergoing cervical debranching to optimize proximal landing zones for TEVAR from 2010 to 2023. Patients were excluded if they had a salvage cervical debranching following an aortic intervention or had an open aortic repair following cervical debranching. Patients were stratified on whether the cervical debranching and TEVAR were staged or synchronous. Cervical debranching was defined as a bypass or transposition of the vessels of the aortic arch (including vertebral artery). The primary outcome was major adverse events (MAEs), which was a composite variable consisting any of the following: 30-day mortality, myocardial infarction, respiratory failure, cerebrovascular accident, hematoma/bleeding, complications, nerve injury, chyle leaks, and acute kidney injury.
A total of 148 patients met study criteria, with 162 cervical debranching procedures performed. There were 112 staged (75.7%) and 36 synchronous (24.3%) patients. There were three patients (2.7%) in the staged cohort that were intended to be staged but did not undergo TEVAR due to complications of their cervical debranching procedure. Synchronous patients were more likely to have non-elective repairs (44.4% vs 18.8%; P = .004) and zone 0 TEVAR deployments (5.5% vs 0%; P = .042) than staged repairs. The overall rate of MAEs for the cohort was 35.8% (n = 53). There were no differences in MAEs between staged and synchronous patients (34.8% vs 38.9%; P = .692). Although not statistically significant, there were lower rates of myocardial infarctions (2.7% vs 8.3%; P = .155), respiratory complications (16.1% vs 30.6%; P = .089), cerebrovascular accidents (11.6% vs 22.2%; P = .167), and bleeding complications (10.7% vs 22.2%; P = .095) in the staged group. The rate of nerve injury for the total cohort was 5.4%, with no differences between the staged and synchronous cohorts (4.5% vs 8.3%; P = .403). The overall technical success rate for cervical debranching procedures was 99.4% (n = 161) with no differences between staged and synchronous procedures (99.1% vs 100%; P = .998). There were no differences in primary, primary-assisted, and secondary patency of the cervical debranching procedures over 5 years between staged and synchronous procedures.
Staged and synchronous cervical debranching and TEVAR had statistically similar perioperative outcomes despite synchronous procedures being performed more often in the non-elective setting. However, there were clinically relevant trends toward better outcomes with staging. Cervical debranching can be performed with a high technical success rate with excellent mid-term patency. Currently, both staged and synchronous strategies appear to be safe and should be tailored towards patients' clinical presentations.
传统上,颈部分支血管离断术用于治疗主动脉弓近端颈部分支的闭塞性疾病。然而,随着血管内技术的发展,颈部分支血管离断术更常用于优化胸主动脉腔内修复术(TEVAR)的近端锚定区。颈部分支血管离断术和TEVAR可以分期或同期进行,关于最佳治疗策略的数据很少甚至没有。因此,本研究的目的是评估分期与同期进行颈部分支血管离断术和TEVAR的患者的预后。
这是一项对2010年至2023年期间接受颈部分支血管离断术以优化TEVAR近端锚定区的患者进行的回顾性单中心研究。如果患者在主动脉干预后进行了挽救性颈部分支血管离断术,或在颈部分支血管离断术后进行了开放性主动脉修复,则将其排除。根据颈部分支血管离断术和TEVAR是分期还是同期进行对患者进行分层。颈部分支血管离断术定义为主动脉弓血管(包括椎动脉)的旁路或移位。主要结局是主要不良事件(MAE),这是一个复合变量,包括以下任何一项:30天死亡率、心肌梗死、呼吸衰竭、脑血管意外、血肿/出血、并发症、神经损伤、乳糜漏和急性肾损伤。
共有148例患者符合研究标准,共进行了162例颈部分支血管离断术。分期手术患者112例(75.7%),同期手术患者36例(24.3%)。分期队列中有3例患者(2.7%)原本计划分期手术,但由于颈部分支血管离断术的并发症而未进行TEVAR。与分期手术相比,同期手术患者更有可能进行非选择性修复(44.4%对18.8%;P = 0.004)和0区TEVAR植入(5.5%对0%;P = 0.042)。该队列的MAE总发生率为35.8%(n = 53)。分期手术和同期手术患者的MAE发生率无差异(34.8%对38.9%;P = 0.692)。尽管无统计学意义,但分期组的心肌梗死发生率(2.7%对8.3%;P = 0.155)、呼吸并发症发生率(16.1%对30.6%;P = 0.089)、脑血管意外发生率(11.6%对22.2%;P = 0.167)和出血并发症发生率(10.7%对22.2%;P = 0.095)较低。整个队列的神经损伤发生率为5.4%,分期和同期队列之间无差异(4.5%对8.3%;P = 0.403)。颈部分支血管离断术的总体技术成功率为99.4%(n = 161),分期和同期手术之间无差异(99.1%对100%;P = 0.998)。分期和同期手术的颈部分支血管离断术在5年内的一期、一期辅助和二期通畅率无差异。
尽管同期手术更多在非选择性情况下进行,但分期和同期颈部分支血管离断术及TEVAR的围手术期结局在统计学上相似。然而,但分期手术有临床相关的更好结局趋势。颈部分支血管离断术可以获得较高的技术成功率和良好的中期通畅率。目前,分期和同期策略似乎都是安全的,应根据患者的临床表现进行调整。